Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Dietary antiplatelets: a new perspective on the health benefits of the water-soluble tomato concentrate Fruitflow®
Online: 2 April 2021
https://www.preprints.org/manuscript/202104.0039/v1?fbclid=IwAR0Ge5DvhK67pnEEzXarSS1zCjoMbatkt5gVYkytbEEziQ0tl9zhPWjOtKc
You're relentless gixer, don't know how you do it but great work.
If you haven't downloaded and read the full article then I recommend it.
Can't say for sure Steve but I would think that it will be peer reviewed.
Looks like DSM have assigned their Oat expert to us
https://www.researchgate.net/search/publication?q=Ruedi%20Duss
W£
Oat expert? Ruedi Fuss is DSM's senior business and marketing manager.
Is it odd that he's named on the white paper alongside Niamh O'Kennedy and Asim Duttaroy?
** Ruedi Duss - mobile auto correct for you.
I wonder what part Ruedi Duss had to play in the writing of the review paper?
3.1. Exercise-induced inflammation
3.2. Air pollution
4. Dietary antiplatelets in immunity (to include COVID-19)
5.1. Platelet hyperactivity during menopause
5.2. Erectile dysfunction
5.2. Allergic responses
Whatever DSM's involvement is in the above.
6. Conclusions
Platelets have multifaceted functions which give rise to a complicated set of interactions with other vascular cells, leading to many roles outside haemostasis. As our understanding of the role of platelet activation in responding to – and in complicating – inflammatory and infectious illnesses grows, it becomes ever clearer that platelet-targeted
treatments are necessary outside the field of CVD. Dietary antiplatelets such as Fruitflow®
could help to provide suitably gentle and safe yet efficacious treatments to improve public
health in response to a wide range of health challenges.
Think DSM know they have 2022 to get a biggy on board as we now have other options
The question is will the biggie focus on my ED or my menopause ?
W!!!
Mighty oaks from little acorns grow
https://medipharm.rs/product/medierect/
We should see a rise on this news monday !
That would be premature - EasterBankHolidayMonday
Back to Ruedi Duss and DSM,
I see the review paper has now had 151 views 46 downloads, Lets hope Mr Duss is forwarding the link to all DSM's customers and potential customers over the weekend.
I see the PXS news section has been updated (first time for a while) with the latest papers although it would have been nice to see it in an RNS.
https://www.provexis.com/news/
This is a fantastic article. Confirms to me 100% why I am still investing in PXS. So many possibilities for heath benefits to people. Going to keep adding with this years ISA allowance as and when funds allow. You can see why BI-health are putting so much money and time into fruitflow. Once they have all the various study's done and approved from blue hat IMO we will be quickly offered a buy out. You can also see why IF is getting all the patents put into place.
Strange that the January news item has been held back and released at this time , I do get the feeling the website is only updated when shareholders find these items .
Fair point. But I got a feeling there is other reasons for it. Still with all the recent new products Gixer and co have found and this article I hope and think the SP will go north starting tomorrow
No RNS no tweet either......